🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 103 of 857 · Phase 3 first, then by program name

  1. Lorundrostat Placebo Tablets, Lorundrostat, Synacthen 0,25 mg/ml Injektionslösung, Lorundrostat

    Mineralys Therapeutics

    Uncontrolled and Resistant Hypertension

    phase 3 small molecule active

    1 trial

  2. Lorundrostat, Lorundrostat, Synacthen 0,25 mg/ml Injektionslösung, Lorundrostat Placebo tablet, Lorundrostat

    Mineralys Therapeutics

    Hypertension

    phase 3 small molecule active

    1 trial

  3. Losartan

    BRIGHT MINDS BIOSCIENCES INC.

    Glomerulonephritis, IGA

    phase 3 small molecule completed

    1 trial

  4. Losmapimod

    Fulcrum Therapeutics

    Facioscapulohumeral Muscular Dystrophy (FSHD)

    phase 3 small molecule terminated

    2 trials

  5. Losmapimod oral tablet

    Fulcrum Therapeutics

    COVID-19

    phase 3 small molecule terminated

    1 trial

  6. Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS)

    United Therapeutics Europe Ltd

    TBI Depression

    phase 3 other completed

    1 trial

  7. Low-dose complex B-vitamins

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hyperhomocysteinemia

    phase 3 other completed

    1 trial

  8. Low-dose rtPA

    Takeda

    Ischemic Stroke

    phase 3 small molecule completed

    1 trial

  9. Lu AA21004

    Takeda

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  10. Lu AF35700

    H. Lundbeck A/S

    Treatment-resistant Schizophrenia

    phase 3 small molecule terminated

    1 trial

  11. Lubiprostone

    Takeda

    Constipation - Functional

    phase 3 small molecule completed

    1 trial

  12. Lubiprostone

    Takeda

    Irritable Bowel Syndrome With Constipation

    phase 3 small molecule completed

    1 trial

  13. Lucentis 10 mg/ml solution for injection, FARICIMAB

    Hoffmann-La Roche

    Choroidal neovascularization secondary to pathologic myopia

    phase 3 small molecule active

    1 trial

  14. Lucentis 10 mg/ml solution for injection, Ranibizumab

    CuraTeQ Biologics s.r.o

    wet macula degeneration

    phase 3 small molecule active

    1 trial

  15. Lucerastat

    Lacuna Pharma Pty Ltd

    Fabry disease

    phase 3 small molecule active

    1 trial

  16. Lucinactant

    WINDTREE THERAPEUTICS INC /DE/

    Meconium Aspiration

    phase 3 small molecule terminated

    1 trial

  17. Lumacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    6 trials

  18. Lumacaftor Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

    phase 3 small molecule completed

    1 trial

  19. Lumacaftor Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

    phase 3 small molecule completed

    1 trial

  20. Lumasiran

    Alnylam Netherlands B.V.

    Primary Hyperoxaluria Type 1

    phase 3 small molecule completed

    1 trial

  21. Lumasiran

    Alnylam Netherlands B.V.

    Primary Hyperoxaluria

    phase 3 small molecule completed

    1 trial

  22. Lurasidone

    Sumitomo Pharma (Suzhou) Co.,

    Bipolar I Depression

    phase 3 small molecule completed

    1 trial

  23. Lutikizumab

    AbbVie

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  24. Lutikizumab, Placebo of Lutikizumab

    AbbVie Deutschland GmbH & Co. KG

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources